Fluid Biopsy Market to Grow with a CAGR of 12.36% through 2028
Rising
Prevalence of chronic diseases are expected to drive the Global Fluid Biopsy
Market in the forecast period 2024-2028.
According to
TechSci Research report, “Fluid Biopsy Market – Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2028”, the Global
Fluid Biopsy Market stood at USD 3197.07 Million in 2022 and is anticipated to
grow with a CAGR of 12.36% in the forecast period, 2024-2028. The growing
prevalence of cancer worldwide is a significant driver. Fluid biopsy's ability
to detect cancer early and monitor disease progression is particularly crucial
in addressing the global cancer burden. Patients and healthcare providers are
increasingly inclined toward non-invasive diagnostic methods. Fluid biopsy
offers a less painful and risky alternative to traditional tissue biopsies. The emphasis on personalized medicine and targeted
therapies has increased the demand for diagnostic tools like fluid biopsy,
which can provide molecular and genetic information to guide treatment
decisions. Ongoing technological advancements, such as next-generation
sequencing and digital PCR techniques, have improved the sensitivity and
accuracy of fluid biopsy tests, making them more reliable. Fluid biopsy allows for continuous and real-time
monitoring of disease progression and treatment responses, facilitating
proactive healthcare interventions. Patients are becoming more proactive in
managing their health, and fluid biopsy aligns with their preferences for less
invasive and more patient-friendly diagnostic procedures. Substantial investments in research and development by
both academic institutions and biotechnology companies are driving innovation
and expanding the applications of fluid biopsy beyond cancer diagnostics. These drivers collectively contribute to the growth
and evolution of the global fluid biopsy market, making it a dynamic and
promising segment within the broader field of diagnostic medicine.
Fluid biopsy,
also known as liquid biopsy, is a cutting-edge medical technique that holds
significant importance in the field of diagnostics and healthcare. It involves
the non-invasive collection and analysis of various biomarkers from bodily
fluids such as blood, urine, or cerebrospinal fluid. The importance of fluid
biopsy lies in its ability to revolutionize disease diagnosis, particularly in
the context of cancer. Unlike traditional tissue biopsies, which can be
invasive, painful, and carry certain risks, fluid biopsy offers a less invasive
and more patient-friendly approach. It enables early detection and monitoring
of diseases, including cancer, by analyzing molecular and genetic markers shed
into bodily fluids. By providing real-time insights into disease status and
progression, fluid biopsy facilitates timely interventions, personalized
treatment strategies, and the potential to significantly improve patient
outcomes. Its non-invasive nature, ability to detect diseases at earlier
stages, and the promise of tailoring therapies to individual patients make
fluid biopsy a critical tool in the advancement of precision medicine and a
game-changer in the diagnosis and management of various medical conditions.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "Global
Fluid Biopsy Market”
The fluid biopsy
market is driven by several key factors that are transforming the landscape of
disease diagnostics and monitoring. One of the primary drivers is the rising
demand for less invasive and more patient-friendly diagnostic methods. Patients
and healthcare providers increasingly favor techniques that reduce discomfort
and minimize the risks associated with traditional tissue biopsies.
Additionally, the growing prevalence of diseases, particularly cancer,
underscores the need for early detection and real-time monitoring, which fluid
biopsy can offer. Technological advancements in next-generation sequencing and
digital PCR are enhancing the sensitivity and accuracy of these tests, boosting
their clinical utility. The trend toward personalized medicine is another
significant driver, with fluid biopsy providing valuable molecular and genetic
information that can guide tailored treatment strategies. Furthermore, advocacy
groups and patient awareness initiatives are pushing for broader accessibility to
these innovative diagnostics, further fueling market growth. The fluid biopsy
market is poised to continue expanding as it aligns with the preferences of
both patients and healthcare providers for non-invasive, precise, and
patient-centric diagnostic solutions.
The Global Fluid
Biopsy Market is segmented into indication, type, regional distribution, and
company.
Based on indication,
the market is segmented into Lung Cancer, Breast Cancer, Colorectal Cancer, and
Other Indications. The Breast Cancer is expected to rise in the forecast
period. This is attribute due to several factors. Breast cancer has a higher
incidence rate globally, making it one of the most commonly diagnosed cancers.
Additionally, there is a strong emphasis on breast cancer awareness, early
detection, and screening programs, which has led to increased diagnosis and
treatment. Breast cancer also benefits from extensive research, resulting in a
wide range of treatment options and targeted therapies. Finally, breast cancer
advocacy has played a significant role in raising awareness and funding,
contributing to its dominant position in terms of research, treatment, and
public attention.
Based on region,
the market is segmented into North America, Europe, Asia Pacific, Central &
South America, Middle East & Africa. The North America segment was
dominated the market in 2022. This is due to the increasing incidence of cancer
in this region and the ongoing research and development efforts. Additionally,
the market's growth is expected to be fueled by the presence of major industry
players and frequent advancements in fluid biopsy products. For example, data
from the American Cancer Society Inc. in 2022 revealed that in 2021,
approximately 1.9 million new cancer cases were diagnosed in the United States
alone. Furthermore, according to data published by the Public Health Agency of
Canada in October 2021, nearly 40% of Canadians were expected to receive a
cancer diagnosis in their lifetime, with around 229,000 Canadians diagnosed with
cancer in 2021. The report also noted that lung, breast, colorectal, and
prostate cancers were projected to remain the most frequently diagnosed types,
accounting for nearly 46% of all cancer diagnoses in 2021. This high prevalence
of cancer in North American countries is anticipated to be a significant
contributing factor to the market's growth.
Major companies operating
in Global Fluid Biopsy Market are:
- Bio-Rad Laboratories
- Guardant Health Inc.
- Illumina, Inc.
- Qiagen NV
- Laboratory Corporation of America Holdings
- F. Hoffmann-La Roche AG
- Thermo Fisher Scientific Inc.
- Johnson & Johnso
- Biocept Inc.
- Bio-Rad Laboratories, Inc
Download Free Sample Report
Customers can
also request for 10% free customization on this report.
“The demand for
less invasive and patient-friendly diagnostic methods is on the rise, with
patients and healthcare providers seeking alternatives to traditional tissue
biopsies that can be invasive and uncomfortable. The increasing incidence of
diseases, especially cancer, emphasizes the need for early detection and
real-time monitoring, which fluid biopsy techniques can provide propell the
growth of global fluid biopsy market. Additionally, the paradigm shift towards
personalized medicine has boosted the relevance of fluid biopsy, as it offers
valuable molecular and genetic information for tailored treatment strategies
and the patient advocacy and awareness initiatives have played a crucial role
in advocating for broader accessibility to these innovative diagnostics which contributes
to foster the demand for Global Fluid Biopsy Market in the forecast period”
said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based management consulting firm.
“Fluid
Biopsy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast,
2018-2028 Segmented By Drug Indication (Lung Cancer, Breast Cancer, Colorectal
Cancer, and Other Indications), By Type (Circulating Tumor Cells, Circulating
Tumor DNA, and Cell-free DNA), By Region and Competition.” has
evaluated the future growth potential of Global Fluid Biopsy Market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Fluid Biopsy Market.
Contact
Techsci Research LLC
420 Lexington Avenue
Suite 300, New York
United States- 10170
M: +13322586602
Email: [email protected]
Web: https://www.techsciresearch.com